Last reviewed 2026-04-20 · How we verify

Agiocur Pregranules

Samsung Medical Center · FDA-approved active Small molecule Quality 0/100

Agiocur Pregranules is a Small molecule drug developed by Samsung Medical Center. It is currently FDA-approved. Also known as: Agio gran..

At a glance

Generic name	Agiocur Pregranules
Also known as	Agio gran.
Sponsor	Samsung Medical Center
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effects of Dietary Fiber on Glucose Control in Subjects With Type 2 Diabetes Mellitus (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Agiocur Pregranules CI brief — competitive landscape report
Agiocur Pregranules updates RSS · CI watch RSS
Samsung Medical Center portfolio CI

Frequently asked questions about Agiocur Pregranules

What is Agiocur Pregranules?

Agiocur Pregranules is a Small molecule drug developed by Samsung Medical Center.

Who makes Agiocur Pregranules?

Agiocur Pregranules is developed and marketed by Samsung Medical Center (see full Samsung Medical Center pipeline at /company/samsung-medical-center).

Is Agiocur Pregranules also known as anything else?

Agiocur Pregranules is also known as Agio gran..

What development phase is Agiocur Pregranules in?

Agiocur Pregranules is FDA-approved (marketed).

Manufacturer: Samsung Medical Center — full pipeline
Also known as: Agio gran.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing